Post by
Duster340 on Dec 05, 2023 10:58pm
P2 jan/1 to march/31
In light of the strong safety and PK data from otenaproxesul’s recent clinical PK/PD study, Antibe is upgrading the design of the upcoming fully-funded Phase II trial. While trial initiation remains set for calendar Q1 2024, the Company now anticipates top-line results in calendar Q3 2024.